Misonix commences direct to hospital sales of its SonaStar Ultrasonic Surgical Aspirator in the US

Sep 2 2009

Misonix, Inc., (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced the second expansion of its direct sales channel for the United States, which was first disclosed in June 2008. In addition to its already established, commission based, contract sales organization, the Company has added 5 experienced, highly trained Region Managers. The Region Managers will support the efforts of the contract sales representatives and will sell Misonix labeled product directly to hospitals and clinics in key markets; including, California, Texas, New York, Florida, and Illinois. In addition to the SonicOne(TM) Wound Management System, which the domestic sales team began to sell in the latter part of calendar 2008, direct to hospital sales of the SonaStar(R) Ultrasonic Surgical Aspirator have now begun. Aesculap, Inc., a division of B. Braun, the German conglomerate, who has sold SonaStar exclusively in the United States in the past, continues to market SonaStar on a non-exclusive basis.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"We are confident that by expanding our domestic sales organization we can grow our revenue in the United States," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "This sales group is designed to increase market penetration and increase revenue for these important products while building customer awareness and brand equity for Misonix. Additionally, we believe this sales team, which is very experienced in the sale of medical equipment and disposables, will provide us with the capability to effectively sell other Misonix labeled products to US clinical customers in the years to come."

Source: http://www.misonix.com